

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



The following tables provide guidance for COVID-19 vaccination schedules based on age and medical condition.

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- Monovalent vaccine should be used for primary series doses. COVID-19 vaccine is a 2- or 3-dose primary series, depending on the recipient's age, immune state and the product used.
- For persons 12 years of age and older, administer a booster dose of bivalent vaccine after the primary series, regardless of the number of previous monovalent booster doses.
- COVID-19 vaccines may be administered on the same day as other vaccines, including influenza vaccine.

**Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age**

Type	Recipient Age	Product*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>†</sup>	Doses	Interval Between Doses
mRNA vaccine	6 months through 5 years	MONOVALENT Moderna: Blue vial cap with magenta-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	6 through 11 years	MONOVALENT Moderna: Blue vial cap with purple-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	12 through 17 years	MONOVALENT Moderna: Red vial cap with blue-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 4 weeks
		Pfizer-BioNTech bivalent vaccine (gray cap) should be used for the booster dose.			Booster dose: Bivalent	
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
	6 months through 4 years	MONOVALENT Pfizer-BioNTech: Maroon vial cap with maroon-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 3 weeks
Doses 2 and 3					At least 8 weeks	Dose 2 to 3
5 through 11 years		MONOVALENT Pfizer-BioNTech: Orange vial cap with orange-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 3 weeks
					Dose 2 to 3	At least 8 weeks
		Booster dose: Monovalent				
Dose 2 to 3	At least 5 months	Dose 3 to 4	At least 3 months			
12 years through 17 years	MONOVALENT Pfizer-BioNTech: Gray vial cap with gray-bordered label	Primary series: Monovalent				
		Dose 1 to 2	At least 3–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 3 weeks	
	Dose 2 to 3			At least 4 weeks		
	BIVALENT - Pfizer-BioNTech: Gray vial cap with gray-bordered label	Booster dose: Bivalent				
Dose 2 to 3		At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)		
Protein subunit vaccine	12 years and older	MONOVALENT Novavax	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks <sup>‡</sup>	Dose 1 to 2	At least 3 weeks
		Pfizer-BioNTech bivalent vaccine (gray cap) should be used for the booster dose.	Booster dose: Bivalent			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)			

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series.

<sup>†</sup> Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

<sup>‡</sup> Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for Persons 6 Months of Age and Older



**Table 2. Immunization Schedule for Persons 18 Years of Age**

Type	Recipient Age	Product*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses†	Doses	Interval Between Doses
mRNA vaccine	18 years and older	<b>MONOVALENT Moderna</b> Red vial cap with a blue-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks‡	Dose 1 to 2	At least 4 weeks
		Dose 2 to 3			At least 4 weeks	
		<b>BIVALENT Moderna</b> Blue cap with gray bordered label	Booster dose: Bivalent			
	Dose 2 to 3		At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
	18 years and older	<b>MONOVALENT Pfizer-BioNTech</b> Gray vial cap with gray-bordered label	Primary series: Monovalent			
Dose 1 to 2			At least 3–8 weeks‡	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3		At least 4 weeks		
<b>BIVALENT Pfizer-BioNTech:</b> Gray vial cap with gray-bordered label		Booster dose: Bivalent				
	Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)		
Protein subunit vaccine	12 years and older	<b>MONOVALENT Novavax</b>	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks‡	Dose 1 to 2	At least 3 weeks
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose: Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)
Adenovirus vector vaccine	18 years and older	<b>MONOVALENT Janssen</b>	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations. <sup>5</sup>			
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose: Bivalent			
			Administer a single booster dose at least 8 weeks (2 months) after the previous dose.			

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

§ For guidance on retrospective record review, scheduling and administration see [www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older




### Special Situations When Vaccinating Children

1. COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is given, count both doses if the recommended interval between doses has been met.
  - Complete the series following the Pfizer-BioNTech 3-dose schedule using an age-appropriate vaccine from either manufacturer. See examples.
  - Repeating doses is not recommended.
- This guidance applies to:
  - All eligible children, including those who are moderately or severely immunocompromised.
  - Vaccines from both manufacturers, regardless which vaccine was given first.

### Examples:

**Vaccination history:** 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.



2. Children who have a birthday before completing the primary series

- Vaccine product and dosage (amount of vaccine given) is determined by the recipient's age.
- CDC recommends administering the age-appropriate product based on the child's age the day the vaccine will be administered – even if the series was started with a vaccine with younger age indications.
- If a dose(s) of the vaccine product indicated for the younger age group is administered, count the dose(s). Revaccination is not indicated. It is NOT considered a vaccine administration error.
- For detailed guidance see:
  - Pfizer-BioNTech COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf))
  - Moderna COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf))

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for Persons 6 Months of Age and Older



**Table 3. COVID-19 Vaccine Products Summary**

Type	Product*	Age Indications†	Diluent	Dose/Injection Amount	
mRNA vaccine	<b>MONOVALENT Moderna:</b> Blue vial cap with magenta-bordered label	6 months through 5 years	NONE	Any dose in the primary series. Booster doses are not recommended for this age group.	25 µg/ 0.25 mL
	<b>MONOVALENT Moderna:</b> Blue vial cap with purple-bordered label	6 through 11 years	NONE	Any dose in the primary series. Booster doses are not authorized for children, ages 6 through 11 years, who received a Moderna primary series.	50 µg/0.5 mL
	<b>MONOVALENT Moderna:</b> Red vial cap with blue-bordered label	12 years and older	NONE	Any dose in the primary series.	100 µg/ 0.5 mL
	<b>BIVALENT Moderna:</b> Blue vial cap with gray-bordered label	18 years and older	NONE	Booster dose	50 µg/0.5 mL
	<b>MONOVALENT Pfizer-BioNTech:</b> Maroon vial cap with maroon-bordered label	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series. Booster doses are not recommended for this age group.	3 µg/0.2 mL
	<b>MONOVALENT Pfizer-BioNTech:</b> Orange vial cap with orange-bordered label	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses	10 µg/0.2 mL
	<b>MONOVALENT Pfizer-BioNTech:</b> Gray vial cap with a gray-bordered label	12 years and older	NONE	Any dose in the primary series	30 µg/0.3 mL
	<b>BIVALENT Pfizer-BioNTech:</b> Gray vial cap with gray-bordered label	12 years and older	NONE	Booster dose	30 µg/0.3 mL
<b>Protein subunit vaccine</b>	<b>MONOVALENT Novavax:</b> Royal blue cap	12 years and older	NONE	Any dose in the primary series.	5 µg rS and 50 µg of Matrix-M™ adjuvant/0.5 mL
<b>Viral vector vaccine</b>	<b>MONOVALENT Janssen</b> Blue Cap	18 years and older	NONE	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations.‡	5×10 <sup>10</sup> viral particles/0.5 mL

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Age-appropriate Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.

‡ For guidance on retrospective record review, scheduling and administration see [www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

## CDC Resources

CDC COVID-19 vaccine clinical training and materials at: [www.cdc.gov/vaccines/covid-19/info-by-product/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)

CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series)

CDC Vaccine administration clinical materials at: [www.cdc.gov/vaccines/hcp/admin/resource-library.html](https://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

CDC Vaccine Storage and Handling Toolkit at: [www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html](https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html)